RAPT THERAPEUTICS INC

RAPT Therapeutics Reports Fourth Quarter and Year End 2021 Financial Results

10 Mar 2022 07:00:02 By Nasdaq GlobeNewswire

RAPT Therapeutics to Participate in the 11th Annual SVB Leerink Healthcare Conference

09 Feb 2022 07:00:01 By Nasdaq GlobeNewswire

RAPT Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

04 Jan 2022 07:00:08 By Nasdaq GlobeNewswire

RAPT Therapeutics Reports Third Quarter 2021 Financial Results

10 Nov 2021 15:05:02 By Nasdaq GlobeNewswire

RAPT Therapeutics Appoints Industry Veteran Lori Lyons-Williams to its Board of Directors

09 Nov 2021 15:01:01 By Nasdaq GlobeNewswire

RAPT Therapeutics to Participate in Upcoming Investor Conferences

08 Nov 2021 07:00:01 By Nasdaq GlobeNewswire

RAPT Therapeutics Announces Upcoming Oral Presentation of RPT193 Phase 1b Data at the 4th Inflammatory Skin Disease Summit

18 Oct 2021 07:00:00 By Nasdaq GlobeNewswire

RAPT Therapeutics Announces Late-Breaking Oral Presentation of Positive Results from Phase 1b Trial of RPT193 at the 30th European Academy of Dermatology and Venereology Congress

30 Sep 2021 08:15:00 By Nasdaq GlobeNewswire

RAPT Therapeutics to Present at the 2021 Cantor Virtual Healthcare Conference

20 Sep 2021 07:00:01 By Nasdaq GlobeNewswire

RAPT Therapeutics to Present RPT193 Phase 1b Data at 30th European Academy of Dermatology and Venereology Congress

20 Sep 2021 07:00:01 By Nasdaq GlobeNewswire

RAPT Therapeutics to Present at Upcoming Investor Conferences

03 Sep 2021 07:00:00 By Nasdaq GlobeNewswire

RAPT Therapeutics Reports Second Quarter 2021 Financial Results

11 Aug 2021 07:00:01 By Nasdaq GlobeNewswire

RAPT Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

18 Jun 2021 11:24:30 By Nasdaq GlobeNewswire

RAPT Therapeutics Announces Pricing of Public Offering of Common Stock

15 Jun 2021 22:07:25 By Nasdaq GlobeNewswire

RAPT Therapeutics Announces Proposed Public Offering of Common Stock

14 Jun 2021 15:01:00 By Nasdaq GlobeNewswire

RAPT Therapeutics Reports Positive Topline Results from Phase 1b Trial of RPT193 Monotherapy in Atopic Dermatitis

14 Jun 2021 07:00:01 By Nasdaq GlobeNewswire

RAPT Therapeutics to Report Top Line Data from Phase 1b Trial of RPT193 in Atopic Dermatitis

13 Jun 2021 15:00:00 By Nasdaq GlobeNewswire

RAPT Therapeutics to Present at the UBS Global Healthcare Virtual Conference

20 May 2021 15:00:00 By Nasdaq GlobeNewswire

RAPT Therapeutics Reports First Quarter 2021 Financial Results

11 May 2021 07:00:02 By Nasdaq GlobeNewswire

RAPT Therapeutics Completes Enrollment in Phase 1b Trial of RPT193 in Atopic Dermatitis

22 Mar 2021 07:00:01 By Nasdaq GlobeNewswire